SOURCE: CDx Diagnostics

CDx Diagnostics

April 30, 2014 09:00 ET

Largest Study of the WATS3D Esophageal Biopsy Will Be Presented at Digestive Disease Week in a Presidential Plenary Session

Additional Three Studies at DDW Will Highlight WATS3D's Ability to Detect Pre-Cancer of the Esophagus

SUFFERN, NY--(Marketwired - Apr 30, 2014) - CDx Diagnostics today announced that five studies examining the WATS3D biopsy will be presented at Digestive Disease Week 2014 (DDW), taking place from May 3-6, 2014 in Chicago. Among the highlights is a presidential plenary session reviewing results from the largest WATS3D clinical study conducted to date. 

The WATS3D biopsy collects a wide area, disaggregated tissue specimen of the entire thickness of the suspect epithelium. This unique tissue specimen is then subjected to specialized, computer-assisted 3-dimensional analysis to pinpoint potentially abnormal cells for presentation to a pathologist. In clinical trials, adjunctive use of WATS3D significantly increased the detection rate of both Barrett's esophagus and esophageal dysplasia. DDW attendees can visit booth # 2711 to learn more about WATS3D.

In addition to the presidential plenary session presentation, other key WATS3D data being presented at DDW include:

  • An oral presentation examining inter-observer agreement among pathologists using WATS3D
  • The first study examining the ability of WATS3D to detect gastric intestinal metaplasia
  • A study examining the benefits of WATS3D in patients with short segment Barrett's esophagus
  • A systematic review and meta-analysis comparing WATS3D to standard endoscopic biopsy alone for detection of Barrett's esophagus and dysplasia

"Our goal is to put esophageal adenocarcinoma on the list of preventable cancers along with cervical cancer, colorectal cancer and skin cancer," said Mark Rutenberg, Chairman and CEO of CDx Diagnostics. "Ten years ago this would have been unthinkable, but new advances in the diagnosis and treatment of the disease are rapidly creating a new paradigm. We believe the data being presented this year at DDW demonstrates the vital role that WATS3D can play in the diagnostic pathway for pre-cancer of the esophagus."

Schedule of WATS3D studies and scientific presentations at DDW 2014

On Sunday, May 4th, beginning at 1:30 PM CDT, the largest WATS3D clinical trial conducted to date will be presented at the ASGE/AGA Joint Presidential Plenary Presentation.

  • "Esophageal Brush Biopsy with Computer-Assisted Tissue Analysis Increases Detection of Barrett's Esophagus and Dysplasia in a Multi-site Community-Based Setting"
    Seth Gross, MD, NYU Langone Medical Center, Vivek Kaul, MD, University of Rochester Medical Center, Anthony Infantolino, MD, Jefferson University Hospitals, Michael S. Smith, MD, Temple University Medical Center

Saturday, May 3, 2014

3:15 PM CDT, Room S401A

  • Oral presentation 165: "Inter-Observer Agreement Among Pathologists Using Wide Area Transepithelial Sampling of Barrett's Esophagus With Computer-Assisted Analysis" 
    Prashanth Vennalaganti, MD, Veterans Affairs Medical Center, Kansas City, MO, Vijay Kanakadandi, MD, Sravanthi Parasa, MD, University of Kansas Medical Center, Kansas City, KS, Seth Gross, MD, NYU Langone Medical Center, Kenneth K. Wang, MD, Mayo Clinic, Rochester, MN, Neil Gupta, MD, Loyola University, Chicago, IL, Prateek Sharma, MD, University of Kansas Medical Center, Kansas City, KS

8:00 AM - 5:00PM CDT, South Hall

  • Poster Sa1664: "Role of Wide Area Transepithelial Sampling for Detecting Gastric Intestinal Metaplasia"
    Kee Don Choi, MD, Muhammad F. Dawwas, MD, Jason Y. Huang, MD, Jason B. Samarasena, MD, Kenneth J. Chang, MD, University of California Irvine

  • Poster Sa1819: "Computer-Assisted Analysis of Esophageal Brush Biopsies Increase the Effectiveness of Screening and Surveillance for Short Segment Barrett's Esophagus"
    DaeWon Kim, MD, Daniel S. Oh, MD, Steven R. DeMeester, MD, Christina L. Greene, MD, Stephanie G. Worrell, MD, Jeffrey A. Hagen, MD, Keck School of Medicine of USC, Los Angeles, CA

  • Poster Sa1833: "Incremental Benefit of Computer-Assisted Brush-Biopsy (WATS3D) Compared to Standard Endoscopic Biopsy for Detection of Barrett's Esophagus and Dysplasia: Systematic Review and Meta-Analysis"
    Lauren B. Gerson, MD, California Pacific Medical Center, Mark Rutenberg, Richard Scott, CDx Diagnostics

About CDx Diagnostics and the WATS3D Biopsy
CDx Diagnostics' mission is to provide doctors with the most powerful diagnostic technology to help prevent cancer before it can start.

CDx Diagnostics' WATS3D biopsy addresses the sampling error inherent in random forceps biopsy testing of the esophagus. In just a few minutes, gastroenterologists can easily obtain a wide area, full-thickness transepithelial tissue sample for computer-assisted 3D laboratory analysis. In clinical trials, adjunctive use of CDx Diagnostics' WATS3D biopsy significantly increased the detection rate of both Barrett's esophagus and esophageal dysplasia. The high sensitivity of WATS3D is due to the large tissue area sampled, and the proprietary 3-Dimensionial computer imaging system that is based on an algorithm developed as part of the U.S. Strategic Defense Initiative missile defense program. To learn more about WATS3D, visit

About Digestive Disease Week®
Digestive Disease Week® (DDW®) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 3 - 6, 2014, at McCormick Place, Chicago, IL. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at

Contact Information